Record full-year 2023 preliminary unaudited revenue of EUR 60.4 million ($65.4 million USD), an increase of 9.6% over full-year 2022, driven by 31.7% HIFU growth Record Q4 2023 preliminary unaudited revenue of EUR 19.6 million ($21.3 million USD), an increase of 24.8% over for Q4 2022, driven by

Record f ull-year 2022 total preliminary unaudited revenue of €55.1 million ($58 .0 million) represents an increase of 25. 1 % over full-year 2021, driven by 58.1% HIFU growth R ecord Q4 2022 total preliminary unaudited revenue of €15. 8 million ($16. 2 million) versus €14.0 million ($15.9 million)

Company completes four Focal One sales, including three bundled sales that combine Focal One® with Exact Imaging’s ExactVu micro ultrasound imaging solution Company recorded an additional three stand-alone ExactVu purchase orders at major centers LYON, France , July 15, 2020 -- EDAP TMS SA (Nasdaq:

Represents f irst s tep towards a potential c linical t reatment of l ocally a dvanced  p ancreatic c ancer LYON, France, January 13, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announces the publication of positive pre-clinical

Study confirms feasibility of using Focal One HIFU to treat rectal endometriosis LYON, France , December 19, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, today announced that Focal One data has been accepted for publication in the journal of

LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced a public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company.

LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced that the price of its public offering of its American Depositary Shares (“ADSs”), which commenced on September 22, 2022, has been set today at $7.50 per

LYON, France, April 23, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced that the price of its offering of American Depositary Shares (“ADS”) has been set at $6.75 per ADS and that the number of offered ADSs is 4,150,000 for an

Company to Participate in Two Plenary Sessions and Five Poster Sessions Ablatherm Treatments Performed During "L.A. Live" Pre-AUA Symposium at USC LYON, France , May 04, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it will

Data demonstrate superiority of HIFU versus radical prostatectomy among prostate cancer patients LYON, France, September 14, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company’s Focal One and ExactVu technologies